

FOR IMMEDIATE RELEASE

Contact: Stephanie Euler
Stern + Associates
(908) 276-4344 ext. 213
stephanie@sternassociates.com

FUJIREBIO DIAGNOSTICS ISSUED PATENT FOR OVARIAN CANCER BIOMARKER
Company to Develop HE4 for Screening, Detection, Monitoring and Prognosis of Disease

MALVERN, Pa., October 31, 2007 – Fujirebio Diagnostics, Inc., the premier cancer diagnostics company, announced today that the United States Patent and Trademark Office has issued a patent for the HE4 biomarker. The company, which was notified of the patent allowance last June, expects this to be the first of a family of patents for this ovarian cancer biomarker.

This patent, covering the measurement of HE4 and antibodies to HE4 in blood, serum and plasma, will allow Fujirebio Diagnostics to continue developing its biomarker for screening, detecting, monitoring and prognosis of ovarian cancer. It also includes claims in which HE4 is used in conjunction with other ovarian cancer markers such as Fujirebio Diagnostics' CA 125, the industry's current gold standard for monitoring ovarian cancer.

“While the medical industry has familiarized the public with warning signs and symptoms of ovarian cancer, there still remains a void of technologies and tools to effectively identify and manage the disease,” said Dr. Olle Nilsson, vice president and chief scientific officer, Fujirebio Diagnostics. “As we’re continually looking for solutions to combat this lethal cancer, this patent gives us the flexibility to explore the use of HE4 at various stages of care from screening and detection to monitoring and prognosis.”

Ovarian cancer is the fifth leading cause of cancer death in women and the second most common female reproductive cancer. This year it is expected that 23,000 women will be diagnosed with ovarian cancer and another 15,000 women will die from the disease. HE4 is a simple blood test and Fujirebio Diagnostics has completed a multi-center clinical trial to evaluate the clinical utility of the test in the more than 250,000 women that are diagnosed with a suspicious pelvic mass in the United States each year.

Commonly referred to as “the silent killer,” ovarian cancer is difficult to diagnose because symptoms can be attributed to a variety of causes. As a result, 70-75 percent of ovarian cancers are diagnosed at a late stage when the five-year overall survival rate is 20-25 percent. However, in women with a diagnosis of Stage I disease, the probability of a cure is 90-95 percent. Early detection of ovarian cancer and surgery performed by a gynecologic oncologist are critical to prolonging life expectancy.

About Fujirebio Diagnostics

Fujirebio Diagnostics is the premier cancer diagnostics company and the industry leader in cancer biomarker assays. Fujirebio Diagnostics specializes in the clinical development, manufacturing and commercialization of *in-vitro* diagnostic products for the management of human disease states, with an emphasis in oncology. Fujirebio Diagnostics is a wholly owned subsidiary of Fujirebio Inc. Fujirebio Inc. is a leading healthcare company in Japan with a focus on diagnostics, and is a group company of Miraca Holdings. Fujirebio Diagnostics has a worldwide distribution network which enables physicians and patients to access its diagnostic products. For more information about Fujirebio Diagnostics, please call 610-240-3800 or visit www.fdi.com.

###